Literature DB >> 17386190

[Risk factors in bronchogenic carcinoma surgery].

José Luis Duque1, Ramón Rami-Porta, Ana Almaraz, Manuel Castanedo, Jorge Freixinet, Antonio Fernández de Rota, Angel López Encuentra.   

Abstract

OBJECTIVE: To analyze the factors that determine the risk of morbidity and mortality associated with lung resection in patients with bronchogenic carcinoma. PATIENTS AND METHODS: Prospective multicenter study conducted between October 1, 1993 and September 30, 1997 in the 19 hospitals that make up the Bronchogenic Carcinoma Cooperative Group. During the study period, 2994 patients with bronchogenic carcinoma underwent surgery. The morbidity and mortality data at 30 days from all centers were recorded in a single registry.
RESULTS: Major resection was performed in 2491 patients, whereas 212 underwent minor resection. The resection had to be extended in 296 and exploratory thoracotomy was carried out in 291. Postoperative complications were reported in 1057 patients (35.2%). Complications directly related to surgery were the most common (22.9%), followed by respiratory (19.5%) and cardiovascular (10.7%) complications. Of the patients with complications, 654 patients (21.8%) had only 1, whereas 403 (13.4%) had more than 1. After classification of complications, 21% were found to be minor and 14.2% were major. Mortality at 30 days was 6.8% (204 patients), and strongly linked to the presentation of major complications--40.8% of those with such complications died.
CONCLUSIONS: Surgical treatment of bronchogenic carcinoma in Spain is associated with high morbidity and mortality. The morbidity reported in the present study lies in the middle of the ranges found in the literature, whereas mortality lies at the high end of the range. The presence of major complications and/or multiple complications should be considered as strong risk factors.

Entities:  

Mesh:

Year:  2007        PMID: 17386190     DOI: 10.1016/s1579-2129(07)60038-x

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  1 in total

1.  The importance of the false-negative rate to validate a staging protocol for non-small cell lung cancer.

Authors:  Carme Obiols; Sergi Call; Ramon Rami-Porta
Journal:  Transl Lung Cancer Res       Date:  2019-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.